R-S-MDMA: Acute Effects of R- and S-MDMA in Healthy Subjects

Sponsor

University Hospital, Basel, Switzerland (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05277636

Collaborator

(none)

Enrollment

Arms

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Racemic ±3,4-methylenedioxymethamphetamine (MDMA) is a psychoactive substance and prototypical empathogen acutely inducing feelings of heightened mood, empathy, trust and closeness to others. These acute subjective effects of MDMA may be helpful to assist psychotherapy and MDMA is currently investigated in phase 3 trials as a possible treatment in post-traumatic stress disorder.

Condition or Disease	Intervention/Treatment	Phase
Healthy	Drug: 3,4-methylenedioxymethamphetamine Drug: S-3,4-methylenedioxymethamphetamine Drug: R-3,4-methylenedioxymethamphetamine (125 mg) Drug: R-3,4-methylenedioxymethamphetamine (250 mg) Other: Placebo	Phase 1

Detailed Description

MDMA is a racemic substance containing equal amounts of the enantiomers S(+)- and R(-)-MDMA. Preclinical research indicates that S-MDMA mainly releases dopamine, norepinephrine, serotonin, and oxytocin while R-MDMA may act more directly on 5-HT2A receptors and release prolactin. Animal studies also indicate that the two enantiomers act synergistically to produce the subjective effects of MDMA and that S-MDMA is mainly responsible for psychostimulation while R-MDMA may have fewer adverse effects and have greater prosocial effects. However, acute effects of S- and R-MDMA have never been validly examined in a human study. Therefore, the present study compares acute responses to R-MDMA, S-MDMA, MDMA, and placebo in a cross-over study in healthy subjects.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

24 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Intervention Model Description:

5-period random order, placebo-controlled, double-blind cross-over study with four active substance conditions and placebo: 1. MDMA (125 mg), 2. S-MDMA (125 mg), 3. R-MDMA (125 mg), 4. R-MDMA (250 mg), 5. Placebo5-period random order, placebo-controlled, double-blind cross-over study with four active substance conditions and placebo:MDMA (125 mg), 2. S-MDMA (125 mg), 3. R-MDMA (125 mg), 4. R-MDMA (250 mg), 5. Placebo

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Basic Science

Official Title:

Acute Effects of R- and S-MDMA in Healthy Subjects

Anticipated Study Start Date :

Jun 30, 2022

Anticipated Primary Completion Date :

Dec 31, 2023

Anticipated Study Completion Date :

Dec 31, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 125 mg MDMA MDMA (125 mg)	Drug: 3,4-methylenedioxymethamphetamine A dose of 125 mg racemic MDMA will be administered. Other Names: MDMA
Experimental: 125 mg S-MDMA S-MDMA (125 mg)	Drug: S-3,4-methylenedioxymethamphetamine A dose of 125 mg enantiomeric S-MDMA will be administered. Other Names: S-MDMA
Experimental: 125 mg R-MDMA R-MDMA (125 mg)	Drug: R-3,4-methylenedioxymethamphetamine (125 mg) A dose of 125 mg enantiomeric R-MDMA will be administered. Other Names: R-MDMA
Experimental: 250 mg R-MDMA R-MDMA (250 mg)	Drug: R-3,4-methylenedioxymethamphetamine (250 mg) A dose of 250 mg enantiomeric R-MDMA will be administered. Other Names: R-MDMA
Placebo Comparator: Placebo Placebo	Other: Placebo Placebo (Mannitol)

Outcome Measures

Primary Outcome Measures

Subjective effects I [18 months]
5 Dimensions of Altered States of Consciousness (5D-ASC) consisting of 94 items to be rated on a visual analog scale (0-100 mm), with higher values indicating stronger effects with higher scores representing more intense effects. Assessed once on each study day
Subjective effects II [18 months]
Stimulation on the Visual Analog Scales (VAS) assessing the intensity and duration of the stimulant effect on a scale from 0 - 100 percent with higher scores representing more intense effects. Assessed 18 times on each study day

Secondary Outcome Measures

Autonomic effects I [18 months]
Assessed 18 times on each study day via systolic and diastolic blood pressure
Autonomic effects II [18 months]
Assessed 18 times on each study day via heart rate
Autonomic effects III [18 months]
Assessed 18 times on each study day via tympanic body temperature
Adverse effects [18 months]
Assessed 3 times on each study day with the list of complaints (LC)
Mood after study day I [18 months]
Assessed once 3 days after administration via the Beck Depressionindex questionnaire (BDI) with low values indicating normal mood and high values indicating severe depression
Mood after study day II [18 months]
Assessed once 3 days after administration via Symptom checklist 90R (SCL-90R) to evaluate a number of different psychological symptoms.
Mood after study day III [18 months]
Assessed once 3 days after administration via list of complaints (LC)
Mood after study day IV [18 months]
Assessed once 3 days after administration via adjective mood rating scale (AMRS)
Plasma levels of cortisol [18 months]
Assessed 3 times on each study day
Plasma levels of prolactin [18 months]
Assessed 3 times on each study day
Plasma levels of oxytocin [18 months]
Assessed 4 times on each study day
Plasma levels of vasopressin [18 months]
Assessed 4 times on each study day
Plasma levels of S-MDMA [18 months]
Assessed 17 times on each study day
Plasma levels of R-MDMA [18 months]
Assessed 17 times on each study day
Plasma levels of S-MDA [18 months]
Assessed 17 times on each study day
Plasma levels of R-MDA [18 months]
Assessed 17 times on each study day
Additional subjective effects I [18 months]
Visual Analog Scales (VAS) assessing the intensity and duration of subjective effects on a scale from 0 - 100 percent with higher scores representing more intense effects. Assessed 18 times on each study day
Additional subjective effects II [18 months]
Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely" assessed 4 times on each study day
States of Consciousness Questionnaire [18 months]
Assesses the emergence and intensity of phenomenons occurring in altered states of consciousness on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely") once on each study day
Spiritual Realms Questionnaire [18 months]
Assesses the spiritual phenomenons elicited by psychedelic substances through 11 main questions to be answered on a total of 65 sub-ordered 100mm visual analog scales once on each study day
Psychological Insight Questionnaire [18 months]
Assesses the degree of psychological insight caused by a psychedelic experience through 14-items to be answered on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely") once on each study day
NEO-Five-Factor-Inventory (NEO-FFI) [Baseline]
The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the "big five": neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from "completely disagree" to "fully agree".
Freiburger Personality Inventory (FPI-R) [Baseline]
The FPI-R version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale ("true" and "not true").
Saarbrücker Personality Questionnaire (SPF) [Baseline]
The SPF defines empathy as the "reactions of one individual to the observed experiences of another." It assesses 28-items on a 5-point Likert scale ranging from "Does not describe me well" to "Describes me very well". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.
HEXACO personality inventory [Baseline]
The HEXACO personality inventory is a six-dimensional model of human personality with 100 items.The six factors are: Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness and Openness to Experience.
Defense Style Questionnaire (DSQ-40) [Baseline]
The DSQ-40 can provide scores for 20 individual defenses, and scores for the three factors "mature", "neurotic", and "immature". Each item is evaluated on a scale from 1 to 9, where "1" indicates "completely disagree" and "9" indicates "fully agree".

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Age between 18 and 65 years.
Understanding of the German language.
Understanding the procedures and the risks that are associated with the study.
Participants must be willing to adhere to the protocol and sign the consent form.
Participants must be willing to refrain from taking illicit psychoactive substances during the study.
Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day.
Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration.
Willing to use double-barrier birth control throughout study participation.
Body mass index between 18-29 kg/m2.

Exclusion Criteria:

Chronic or acute medical condition
Current or previous major psychiatric disorder
Psychotic disorder in first-degree relatives, not including psychotic disorders secondary to an apparent medical reason, e.g. brain injury, dementia, or lesions of the brain.
Hypertension (SBP>140/90 mmHg) or hypotension (SBP<85 mmHg)
Illicit substance use (not including cannabis) more than 20 times or any time within the previous month
Pregnant or nursing women.
Participation in another clinical trial (currently or within the last 30 days).
Use of medications that may interfere with the effects of the study medications.
Tobacco smoking (>10 cigarettes/day).
Consumption of alcoholic drinks (>15 drinks/week).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

University Hospital, Basel, Switzerland

Investigators

Principal Investigator: Matthias E Liechti, MD, University Hospital Basel, Basel, Switzerland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

University Hospital, Basel, Switzerland

ClinicalTrials.gov Identifier:

NCT05277636

Other Study ID Numbers:

BASEC 2021-02386

First Posted:

Mar 14, 2022

Last Update Posted:

Mar 31, 2022

Last Verified:

Mar 1, 2022

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

N-Methyl-3,4-methylenedioxyamphetamine

Study Results

No Results Posted as of Mar 31, 2022